Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)

Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)
Name	Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)
Formation	2020
Purpose	Public–private partnership to coordinate COVID-19 clinical trials, therapeutics, and vaccines
Headquarters	United States

Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) was a public–private partnership launched in 2020 to coordinate and accelerate clinical research for SARS‑CoV‑2 countermeasures. Founded amid the global COVID‑19 pandemic, the initiative brought together federal agencies, pharmaceutical companies, academic institutions, and philanthropic organizations to streamline trials, harmonize protocols, and prioritize resources.

Background and Formation

The initiative was announced by the National Institutes of Health in collaboration with the Operation Warp Speed program and engaged partners such as the Food and Drug Administration, Centers for Disease Control and Prevention, and the Biomedical Advanced Research and Development Authority. Key founding participants included Pfizer, Moderna, Inc., AstraZeneca, Johnson & Johnson, and Merck & Co., Inc. alongside academic centers like the Johns Hopkins University and the University of Oxford. High-profile stakeholders such as the Bill & Melinda Gates Foundation and the Wellcome Trust provided philanthropic alignment, while regulatory and policy coordination involved actors like the Office of Management and Budget and the White House Coronavirus Task Force.

Governance and Participating Organizations

ACTIV operated under a leadership framework that included representatives from the National Institutes of Health, the Food and Drug Administration, the Department of Defense, and representatives from major pharmaceutical corporations including Gilead Sciences, Regeneron Pharmaceuticals, and GlaxoSmithKline. Academic governance voices represented institutions such as the Massachusetts Institute of Technology, the Harvard Medical School, and the University of California, San Francisco. International collaboration drew on expertise from organizations like the World Health Organization and the European Medicines Agency, while philanthropic oversight involved the Howard Hughes Medical Institute and the Rockefeller Foundation.

Objectives and Strategic Priorities

Primary objectives emphasized accelerating candidate therapeutics and vaccines by harmonizing master protocols, prioritizing candidates for phase trials, and establishing shared resources with partners including BARDA and CEPI. Strategic priorities aligned with rapid evaluation of antiviral agents from companies like Roche and neutralizing antibodies from entities such as Eli Lilly and Company and Regeneron Pharmaceuticals. The program sought to optimize endpoints used by trial networks tied to the National COVID Cohort Collaborative and to expedite regulatory reviews involving the Food and Drug Administration and international regulators like the European Medicines Agency.

Major Clinical Trials and Therapeutic Programs

ACTIV coordinated or supported trial platforms comparable to the RECOVERY Trial at University of Oxford and adaptive platforms influenced by designs from the Adaptive COVID‑19 Treatment Trial led by the National Institutes of Health. Notable therapeutic evaluations included antiviral trials of remdesivir developed by Gilead Sciences, monoclonal antibody studies involving Regeneron Pharmaceuticals and Eli Lilly and Company, and immunomodulator trials assessing agents from AbbVie and Sanofi. ACTIV’s trial harmonization interfaced with large networks such as INSIGHT and the Global Fund-linked consortia, while data from hospital systems like Mount Sinai Health System and Mayo Clinic fed into analyses.

Vaccine Development and Evaluation Efforts

ACTIV’s vaccine efforts complemented programs at Moderna, Inc., Pfizer, and AstraZeneca, and sought to standardize immunogenicity assays with laboratories including the National Institute for Biological Standards and Control and the Fred Hutchinson Cancer Center. The partnership worked to prioritize candidates for efficacy testing that paralleled phase trials by University of Oxford/AstraZeneca and spurred harmonization with regulatory frameworks from the Food and Drug Administration and the European Medicines Agency. ACTIV also coordinated correlative studies with biobanks at institutions such as the Broad Institute and Scripps Research.

Data Sharing, Standardization, and Biomarkers

ACTIV emphasized data standardization alongside initiatives like the Observational Health Data Sciences and Informatics consortium and the National COVID Cohort Collaborative, promoting common data models and case report forms used by Centers for Disease Control and Prevention surveillance systems and academic data platforms at Stanford University. Biomarker work engaged laboratories including the National Cancer Institute and the Vanderbilt University Medical Center to validate immunologic correlates comparable to efforts at the London School of Hygiene & Tropical Medicine. The partnership advocated interoperable data standards aligned with policies from the Office of the National Coordinator for Health Information Technology.

Outcomes, Impact, and Lessons Learned

ACTIV contributed to accelerated evidence generation that informed emergency use authorizations issued by the Food and Drug Administration and policy guidance from the World Health Organization, supporting therapeutics such as antiviral and monoclonal antibody treatments adopted in clinical practice at centers like Cleveland Clinic and Johns Hopkins Hospital. The initiative demonstrated the utility of adaptive platform trials modeled on the RECOVERY Trial and Adaptive COVID‑19 Treatment Trial, highlighted challenges in global trial equity involving entities like Médecins Sans Frontières and underscored the importance of sustained public–private coordination seen in partnerships with BARDA and the Bill & Melinda Gates Foundation. Lessons informed pandemic preparedness frameworks considered by the National Academies of Sciences, Engineering, and Medicine and future responses coordinated with the World Health Organization.

Category:COVID-19 pandemic